SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...

Related Keywords

Spain , Australia , Rockville , Pennsylvania , United States , China , Madrid , Nanfang , Guangdong , Florida , Hong Kong , Peking , Beijing , Texas , Suzhou , Jiangsu , Philadelphia , Lu Yu , Sikander Ailawadhi , Ascentage Pharma , Yifan Zhai , Junjie Chen , Prnewswire Ascentage Pharma , Southern Medical University , European Hematology Association , China National Medical Products Administration , Astrazeneca , Ascentage Pharma Group Inc , University Of Texas Md Anderson Cancer Center , Dana Farber Cancer Institute , Md Anderson Cancer Center , Major National , National Reimbursement Drug List , Embryonic Ectoderm Development , University People Hospital , European Hematology Association Hybrid Congress , Poster Presentations , Hematology Association Hybrid Congress , Hybrid Congress , Chief Medical Officer , Overcomes Ponatinib , Asciminib Resistance , Heavily Pretreated Chronic Myeloid Leukemia , Presentation Type , Friday June , Presenting Author , Third Generation , New Diagnosed Adult , Nanfang Hospital , Southern Medical , Reported Outcomes , Resistant Chronic Myeloid Leukemia Receiving , Peking University People , Novel Therapeutic Regimens , Multiple Myeloma , Immunoglobulin Light Chain , Mayo Clinic , Ectoderm Development , Chronic Kidney , Induced Hemoglobin , Preclinical Models , Ascentage Pharma Group , Main Board , Stock Exchange , Hong Kong Limited , Major National Rd Projects , Major New Drug Projects , New Drug Incubator , Innovative Drug Programs , Major Project , Priority Review Designations , Breakthrough Therapy Designations , Drug Evaluation , Reimbursement Drug List , Orphan Drug Designation , Fast Track Designation , Orphan Designation , Cancer Center ,